Macfarlanes has acted for Hayfin Capital Management (“Hayfin”) in relation to a new 5 year term facility of £35.0 million and a £3.0 million revolving credit facility for AIM-listed Sinclair IS Pharma plc (“Sinclair”), the international specialty pharmaceutical company.

The facility has been used to repay all borrowings under Sinclair's existing debt facility with Clydesdale Bank plc, and to fund payments for the acquisition of the global rights to Perfectha™ dermal fillers through the acquisition of Obvieline Laboratories SA and of distribution rights in Brazil and Russia from Pharmavital SA, Obvieline's parent company for a total consideration of up to €32.2 million (£26.7 million) in cash with an initial payment of €10.0 million (£8.3 million). The acquisition of Obvieline completed on 6 January 2014 and the acquisition from Pharmavital is expected to close within six months.

Banking and finance partner Andrew Perkins led the Macfarlanes team, supported by senior solicitor Jonathan Keil and solicitor Adam Caines.  Andrew Perkins commented: "We were delighted that Hayfin instructed us to help them close this multi-jurisdictional deal in a short time frame and that we were again able to support the growth of the Hayfin business."